Intestinal Endotoxemia and Beta- Cell Dysfunction in Prediabetics

ConditionsPrediabetic State (IGT)Prediabetic State

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18-65

SponsorSohag University

About this trial

the goal of this observation study is to learn about association between intestinal endotoxemia and prediabetes lean patients with the aim of prevention of diabetes in those category of patients

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age: 18-65 years

BMI: 18.5-24.9 kg/m²

ADA prediabetes: FPG 100-125 mg/dL OR 2hPG 140-199 mg/dL OR HbA1c 5.7-6.4%

HOMA-IR <1.5 (key inclusion criterion)

Disqualifiers

- HOMA-IR ≥1.5

BMI ≥25 kg/m²

Diabetes, acute inflammation, GI disorders (Table 1) Group II (Controls): Lean normoglycemic ; age and sex-matched healthy subjects

Trial population

The patient population for the trial will be derived from Outpatient clinics, Sohag University Hospital 120 participants .

Trial design

Design model

Case-control

Time perspective

Cross-sectional

Treatments tested in this trial

hba1c, lbp, fasting blood sugar, lipogram, fastinf insulin
Diagnostic test
diagnostic tests for prediabetes and intestinal endotoxemia

Treatment groups

120 Participants

are divided into 2 treatment groups

Group A: group 1: cases1 intervention

Group B: group 2:controls1 intervention

Trial outcomes

Primary outcomes

correlation between intestinal endotoxemia (measured by serum LBP) and basal beta-cell dysfunction (HOMA-B) in lean prediabetic patients

To determine the correlation between intestinal endotoxemia (measured by serum LBP) and basal beta-cell dysfunction (HOMA-B) in lean prediabetic patients with minimal insulin resistance (HOMA-IR \<1.5).

Time frame

one year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Sohag University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: